3 Stocks Underperforming Today In The Health Care Sector

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

All three major indices are trading down today with the Dow Jones Industrial Average ( ^DJI) trading down 77 points (-0.4%) at 17,034 as of Tuesday, Sept. 9, 2014, 12:55 PM ET. The NYSE advances/declines ratio sits at 824 issues advancing vs. 2,132 declining with 162 unchanged.

The Health Care sector currently sits down 0.2% versus the S&P 500, which is down 0.3%. On the negative front, top decliners within the sector include Illumina ( ILMN), down 1.4%, Celgene ( CELG), down 1.1%, Biogen Idec ( BIIB), down 0.9%, Amgen ( AMGN), down 0.8% and Pfizer ( PFE), down 0.7%. Top gainers within the sector include HCA Holdings ( HCA), up 2.6%, Universal Health Services ( UHS), up 2.6%, Novo Nordisk A/S ( NVO), up 2.4%, AbbVie ( ABBV), up 2.1% and Covidien ( COV), up 1.9%.

TheStreet would like to highlight 3 stocks pushing the sector lower today:

3. Vertex Pharmaceuticals ( VRTX) is one of the companies pushing the Health Care sector lower today. As of noon trading, Vertex Pharmaceuticals is down $1.22 (-1.3%) to $93.28 on light volume. Thus far, 453,354 shares of Vertex Pharmaceuticals exchanged hands as compared to its average daily volume of 2.1 million shares. The stock has ranged in price between $93.07-$94.48 after having opened the day at $94.17 as compared to the previous trading day's close of $94.49.

Vertex Pharmaceuticals Incorporated is engaged in discovering, developing, manufacturing, and commercializing small molecule drugs for patients with serious diseases. Vertex Pharmaceuticals has a market cap of $22.6 billion and is part of the drugs industry. Shares are up 27.2% year-to-date as of the close of trading on Monday. Currently there are 9 analysts that rate Vertex Pharmaceuticals a buy, no analysts rate it a sell, and 5 rate it a hold.

TheStreet Ratings rates Vertex Pharmaceuticals as a hold. The company's strengths can be seen in multiple areas, such as its increase in stock price during the past year and largely solid financial position with reasonable debt levels by most measures. However, as a counter to these strengths, we also find weaknesses including feeble growth in the company's earnings per share, unimpressive growth in net income and disappointing return on equity. Get the full Vertex Pharmaceuticals Ratings Report now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

2. As of noon trading, Teva Pharmaceutical Industries ( TEVA) is down $1.03 (-2.0%) to $51.55 on average volume. Thus far, 1.9 million shares of Teva Pharmaceutical Industries exchanged hands as compared to its average daily volume of 3.9 million shares. The stock has ranged in price between $51.45-$52.48 after having opened the day at $52.43 as compared to the previous trading day's close of $52.58.

Teva Pharmaceutical Industries Limited, together with its subsidiaries, develops, manufactures, sells, and distributes pharmaceutical products worldwide. The company offers generic pharmaceutical products; and basic chemicals, as well as specialized product families. Teva Pharmaceutical Industries has a market cap of $44.4 billion and is part of the drugs industry. Shares are up 31.2% year-to-date as of the close of trading on Monday. Currently there are 10 analysts that rate Teva Pharmaceutical Industries a buy, no analysts rate it a sell, and 10 rate it a hold.

TheStreet Ratings rates Teva Pharmaceutical Industries as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, solid stock price performance, attractive valuation levels, compelling growth in net income and good cash flow from operations. Although no company is perfect, currently we do not see any significant weaknesses which are likely to detract from the generally positive outlook. Get the full Teva Pharmaceutical Industries Ratings Report now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

1. As of noon trading, Thermo Fisher Scientific ( TMO) is down $0.79 (-0.6%) to $124.19 on light volume. Thus far, 644,353 shares of Thermo Fisher Scientific exchanged hands as compared to its average daily volume of 1.7 million shares. The stock has ranged in price between $124.07-$124.95 after having opened the day at $124.78 as compared to the previous trading day's close of $124.98.

Thermo Fisher Scientific Inc. provides analytical instruments, equipment, reagents and consumables, software, and services for research, manufacturing, analysis, discovery, and diagnostics in the United States and internationally. Thermo Fisher Scientific has a market cap of $49.8 billion and is part of the health services industry. Shares are up 12.2% year-to-date as of the close of trading on Monday. Currently there are 12 analysts that rate Thermo Fisher Scientific a buy, no analysts rate it a sell, and none rate it a hold.

TheStreet Ratings rates Thermo Fisher Scientific as a buy. The company's strengths can be seen in multiple areas, such as its robust revenue growth, solid stock price performance, reasonable valuation levels, increase in net income and good cash flow from operations. We feel these strengths outweigh the fact that the company has had somewhat disappointing return on equity. Get the full Thermo Fisher Scientific Ratings Report now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

If you are interested in one of these 3 stocks, ETFs may be of interest. Investors who are bullish on the health care sector could consider Health Care Select Sector SPDR ( XLV) while those bearish on the health care sector could consider ProShares Ultra Short Health Care ( RXD).

null

More from Markets

Jim Cramer on Earnings: All Stories Aren't Equal

Jim Cramer on Earnings: All Stories Aren't Equal

Stocks Seek Direction Amid a Rise in Bond Yields, Strong Earnings

Stocks Seek Direction Amid a Rise in Bond Yields, Strong Earnings

4 Stocks Making Important Moves Wednesday

4 Stocks Making Important Moves Wednesday

Dow Futures Turn Positive After Boeing Earnings Blowout; Twitter Boosts Nasdaq

Dow Futures Turn Positive After Boeing Earnings Blowout; Twitter Boosts Nasdaq

Facebook, Boeing, Shire and Credit Suisse - 5 Things You Must Know

Facebook, Boeing, Shire and Credit Suisse - 5 Things You Must Know